Home » Stocks » BTHE

Boston Therapeutics Inc. (BTHE)

Stock Price: $0.0247 USD 0.0047 (23.50%)
Updated Jun 11, 2021 12:09 PM EDT - Market closed
Market Cap 22.65M
Revenue (ttm) 9,336
Net Income (ttm) -907,883
Shares Out 916.92M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $0.0247
Previous Close $0.0200
Change ($) 0.0047
Change (%) 23.50%
Day's Open 0.0247
Day's Range 0.0247 - 0.0247
Day's Volume 524
52-Week Range 0.0055 - 0.0600

News

There are no news available yet.

About BTHE

Boston Therapeutics, Inc., a pre-clinical and clinical-stage pharmaceutical development company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements in the United States. The company's lead pharmaceutical drug candidates are BTI-320, a non-systemic carbohydrate-based compound that is in Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic and pre diabetic patients; BTI-410, a peptide injectable compound that has completed Phas... [Read more...]

Industry
Biotechnology
Founded
2009
Stock Exchange
OTCMKTS
Ticker Symbol
BTHE
Full Company Profile

Financial Performance

In 2020, BTHE's revenue was $9,336, a decrease of -42.83% compared to the previous year's $16,329. Losses were -$907,883, -75.42% less than in 2019.

Financial Statements